Related Experiment Video
Updated: Jul 18, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
[Cardiac natriuretic peptides in heart failure]
Dubravka Cvorisćec1, Ivana Cepelak
1Klinidki zavod za laboratorijsku dijagnostiku Medicinskog fakulteta Sveucilista u Zagrebu i KBC Zagreb
Lijecnicki Vjesnik
|November 30, 2006
Summary
Natriuretic peptides are key biomarkers for diagnosing and assessing risk in chronic heart failure patients. Research highlights their importance, though optimal assay methods require further consensus.
Area of Science:
- Biochemistry
- Cardiology
- Clinical Diagnostics
Context:
- Heart failure involves complex cardiac, muscular, and renal dysfunctions, alongside neurohormonal alterations.
- Early diagnosis and treatment are crucial for managing heart failure morbidity and mortality.
- Natriuretic peptides have emerged as vital biochemical markers in chronic heart failure management.
Purpose:
- To review the role of natriuretic peptides in diagnosing and stratifying risk for chronic heart failure.
- To discuss the natriuretic peptide family and their diagnostic utility.
- To address the ongoing debate regarding the most reliable assay methods for natriuretic peptides.
Summary:
- Natriuretic peptides are increasingly recognized for their diagnostic and prognostic value in heart failure.
- The natriuretic peptide family consists of four distinct peptides with a shared structural motif.
- While European guidelines acknowledge their importance, consensus on the optimal assay method is still lacking, with non-competitive immunoassays suggested for clinical use.
Impact:
- Establishes natriuretic peptides as essential tools for heart failure diagnosis and risk assessment.
- Informs clinical practice and guideline development regarding heart failure management.
- Highlights the need for standardization in natriuretic peptide testing to improve patient outcomes.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...